Evaxion A/S (NASDAQ:EVAX) Now Covered by Analysts at JonesTrading

Investment analysts at JonesTrading started coverage on shares of Evaxion A/S (NASDAQ:EVAX) in a report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $10.00 price target on the stock. JonesTrading’s price objective points to a potential upside of 178.32% from the stock’s current price.

Several other equities analysts also recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research note on Friday, January 9th. Maxim Group began coverage on Evaxion A/S in a research note on Thursday, February 19th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Lake Street Capital decreased their target price on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a report on Monday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.00.

Evaxion A/S Stock Performance

EVAX stock traded up $0.51 during trading on Tuesday, reaching $3.59. The company had a trading volume of 28,746 shares, compared to its average volume of 52,085. The company has a market cap of $29.97 million, a price-to-earnings ratio of -2.65 and a beta of 0.28. Evaxion A/S has a twelve month low of $1.20 and a twelve month high of $12.15. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.85 and a current ratio of 5.85. The firm has a 50-day simple moving average of $3.87 and a 200-day simple moving average of $4.63.

Evaxion A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.30 earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Evaxion A/S will post -0.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. acquired a new position in Evaxion A/S in the fourth quarter valued at approximately $38,000. Wesbanco Bank Inc. acquired a new stake in shares of Evaxion A/S during the 4th quarter worth approximately $48,000. Finally, SmartHarvest Portfolios LLC purchased a new position in shares of Evaxion A/S during the 4th quarter valued at approximately $72,000. 11.04% of the stock is currently owned by hedge funds and other institutional investors.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.